The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2019 | CLL treatment: novel agents vs. cellular therapies
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the debate held between academics as to the efficacy and toxicities of cellular therapies compared to novel agents and the roles both are to play in the future of chronic lymphocytic leukemia (CLL) treatment. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
